Masimo Renews Agreement with Amerinet for Masimo SET Pulse Oximetry and Adds New Masimo Rainbow SET™ Technology
"We are pleased to announce the renewal of our agreement with Amerinet," explained Masimo Chairman and CEO Joe E. Kiani. "And we believe that Amerinet members will be pleased to continue to have access to superior Masimo SET pulse oximetry products as well as the new Masimo Rainbow SET technology that will allow for the earlier detection and treatment of an expanding number of potentially life-threatening conditions."
Masimo SET technology allows clinicians to obtain accurate pulse oximetry readings even in situations of motion and low-perfusion, and has been proven more accurate and reliable in the most challenging clinical settings by over 70 peer reviewed published clinical studies. Building on this technology platform, Masimo has recently introduced Masimo Rainbow SET, world's first device capable of noninvasively measuring carboxyhemoglobin, methemoglobin and oxyhemoglobin saturation levels in the blood
In clinical studies and in the field, Masimo Rainbow SET is already proving itself effective in detecting carbon monoxide poisoning in seconds, allowing accurate diagnosis and early treatment of a life-threatening problem that is frequently misdiagnosed as flu or migraine. In addition, a recent Johns Hopkins study found that methemoglobinemia, a potentially lethal condition that starves the tissues of oxygen, is much more common in hospitalized patients than previously realized.
Amerinet is one of the most innovative and effective health care group purchasing organizations in the United States, partnering with members to improve their operating margins. More than 2,100 hospitals and 35,000 non-acute care facilities create new revenue and reduce expenses with Amerinet's tools for group purchasing, supply chain management, clinical consulting, revenue cycle management, and information and education.
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 100 clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com
Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.
Contact: Tom McCall
Vice President, Corporate Communications